OPKO Health(US:OPK)2025-10-29 20:11Financial Performance - Total consolidated revenues for Q3 2025 were $151.7 million, down from $173.6 million in Q3 2024, representing a decrease of approximately 12.0%[3] - Operating income for Q3 2025 was $48.1 million, compared to $14.2 million in Q3 2024, indicating a significant improvement[3] - Net income for Q3 2025 was $21.6 million, or $0.03 per diluted share, compared to $24.9 million, or $0.03 per diluted share, in the prior year[3] - Total revenues for the three months ended September 30, 2025, were $151.7 million, a decrease of 12.6% compared to $173.6 million for the same period in 2024[14] - Revenue from services was $95.2 million, down 21.5% from $121.3 million year-over-year[14] - Net income for the three months ended September 30, 2025, was $21.6 million, compared to $24.9 million in the same quarter of 2024, reflecting a decrease of 13.3%[14] - Total costs and expenses for the three months ended September 30, 2025, were $103.6 million, down from $159.4 million in the same quarter of 2024, a decrease of 34.9%[14] Revenue Breakdown - Revenue from pharmaceuticals in Q3 2025 was $37.7 million, a slight decrease from $39.1 million in Q3 2024, while Rayaldee sales increased to $7.5 million from $5.8 million[3] - Revenue from diagnostics services in Q3 2025 was $95.2 million, down from $121.3 million in Q3 2024, primarily due to lower clinical test volumes[3] Cash and Investments - Cash, cash equivalents, and restricted cash totaled $428.9 million as of September 30, 2025, including $173.3 million received from the Labcorp transaction[3][4] - Approximately $73.8 million of OPKO's common stock had been repurchased under the buyback program since its authorization in July 2024, with $126.2 million remaining available for future repurchases[4] - The company reported a loss from investments in investees of $0.0 million, consistent with the previous year[14] Research and Development - Research and development expenses increased to $30.1 million, up 4.5% from $28.8 million in the prior year[14] Collaborations and Approvals - The collaboration with Regeneron Pharmaceuticals could yield potential milestone payments exceeding $200 million for each program, with overall collaboration value potentially exceeding $1 billion[1] - The FDA approved a supplemental application for the 4Kscore® Test, enhancing its use without digital rectal examination information, supported by studies showing over 96% sensitivity and accuracy[2] Stock and Shares - The weighted average common shares outstanding, basic, increased to 777,154,808 from 694,622,466 year-over-year[14] - Income (loss) per share, basic, was $0.03 for the three months ended September 30, 2025, compared to $0.04 for the same period in 2024[14] Cost Management - The cost of service revenues decreased to $80.4 million from $108.8 million, a reduction of 26.1% year-over-year[14]